MRVL: 7% | Google Teams Up With Marvell Technology To Build New AI Chips, Invests Heavily In TPU Strategy Amid Nvidia Dominance: Report

 

CMND: 110% | Clearmind Medicine Says CMND-100, Proprietary Non-Hallucinogenic MEAI-Based Oral Drug Candidate, For Treatment Of AUD Met Primary Endpoint In Its FDA-Approved Phase I/IIa Clinical Trial

 

CMPS: 30% | Compass Pathways Welcomes The White House Executive Order On Accelerating Medical Treatments For Serious Mental Illness